指南与共识炎症性肠病消化道肿瘤与早癌

AGA临床实践更新:恶性肿瘤患者炎症性肠病的管理述评

AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary.
指南 / 共识 · Clin Gastroenterol Hepatol · 2024-05-14

美国胃肠病学会(AGA)研究所发布的临床实践更新述评,讨论炎症性肠病(IBD)患者各类恶性肿瘤风险及现有药物治疗对这些风险的影响,并为罹患恶性肿瘤或有癌症史的IBD患者的用药管理提供指导。该述评经AGA研究所临床实践更新委员会和理事会委托批准,并经内部及外部同行评议。

要点

  • 讨论IBD患者各类恶性肿瘤风险及药物治疗对这些风险的影响。
  • 指导罹患恶性肿瘤或有癌症史的IBD患者的IBD用药管理。
  • 述评经AGA研究所委员会及理事会批准,并完成内外部同行评议。

核心结论

  • 该述评讨论IBD患者各类恶性肿瘤风险及现有药物治疗对这些风险的影响,并为罹患恶性肿瘤或有癌症史的IBD患者提供用药管理指导。

研究设计与样本

  • 美国胃肠病学会(AGA)研究所临床实践更新委员会和理事会委托并批准的临床实践更新述评,经内部同行评议及《Clinical Gastroenterology and Hepatology》标准程序外部同行评议,纳入该领域近期发表的重要研究并反映作者经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) Commentary is to discuss the risks of various malignancies in patients with inflammatory bowel diseases (IBD) and the impact of the available medical therapies on these risks. The CPU will also guide the approach to the patient with IBD who develops a malignancy or the patient with a history of cancer in terms of IBD medication management. METHODS: This CPU was commissioned and approved by the AGA Institute CPU committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership and underwent internal peer review by the CPU committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. This communication incorporates important and recently published studies in the field, and it reflects the experiences of the authors who are experts in the diagnosis and management of IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Axelrad JE, Hashash JG, Itzkowitz SH, et al. AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary. Clin Gastroenterol Hepatol. 2024. PMID: 38752967. doi:10.1016/j.cgh.2024.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。